Company Profile
Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. The company uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. It offers toolbox of mice.
Its portfolio also includes disease mice, such as rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor, and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic and targets
Cytokine reporters, inducible cell ablation, and cell-specific reporters other models comprising rats, such as humanized drug target, immunodeficient, diseases, reporters, and cre-drivers.
Its portfolio also includes standard strains including inbred and outbred, cells model, which includes reporter labeled, primary, wild-type, and other, and supporting solutions including colony management, such as cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services
Auxiliary apparatuses, such as e-BLOT WB imaging system. Additionally, it offers model customization including includes gene editing technology, such as ES cell targeting, CRISPR gene editing, and transgene.
Its portfolio also includes genetically engineered type model, which includes conventional and conditional knockout, KO first, knock-in, point mutation, conditional point mutation, humanization, targeted conditional overexpression, and random transgene, and surgery and preconditioning
Preclinical services, which includes non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics. It offers treatment for various therapeutic areas, such as oncology; nervous system, autoimmune, and digestive system diseases. Founded in 2000, the company is headquartered in Shanghai, China.